|
DE3613736A1
(de)
*
|
1985-04-26 |
1986-10-30 |
Adalbert 8261 Reischach Hayduk |
Vorrichtung zur hautvertraeglichen befestigung von behandlungselementen der akupunktur-therapie am ohr von patienten
|
|
USRE35511E
(en)
*
|
1990-12-18 |
1997-05-20 |
Nakamura; Azuko |
Accessory for earring
|
|
US5097682A
(en)
*
|
1990-12-18 |
1992-03-24 |
Azuko Nakamura |
Accessory for earring
|
|
WO1993008712A1
(en)
*
|
1991-11-08 |
1993-05-13 |
Leona Gray Loureiro |
Jewelry and apparel fixation
|
|
FR2703568A1
(fr)
*
|
1993-04-09 |
1994-10-14 |
Muller Dominique |
Système de fixation de boucles d'oreilles.
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
GB2304533A
(en)
*
|
1995-08-24 |
1997-03-26 |
Bun Wong |
Personal decoration composed of precious stone with magnet insert.
|
|
US5989178A
(en)
*
|
1997-04-02 |
1999-11-23 |
Chiu; Alexander Y. C. |
Magnetic ring
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
FR2777364B1
(fr)
*
|
1998-04-08 |
2000-06-16 |
Andre Jevanoff |
Montre presentant un bloc-montre pourvu d'au moins une parure interchangeable formant bijou
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
HK1047236A1
(zh)
*
|
1999-05-14 |
2003-02-14 |
Imclone Llc |
用表皮生长因子受体拮抗剂治疗难治的人肿瘤
|
|
GB2356291B
(en)
|
1999-11-13 |
2003-10-22 |
Rolls Royce Plc |
A workpiece clamping system
|
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6305192B1
(en)
|
2000-09-11 |
2001-10-23 |
Inverness Corporation |
Apparatus for increasing piercing safety
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
US6715315B1
(en)
|
2002-09-23 |
2004-04-06 |
Heart & Company |
Jewelry articles having magnetic elements and interchangeable settings
|
|
DE10320863B3
(de)
*
|
2003-05-09 |
2004-11-11 |
Siemens Audiologische Technik Gmbh |
Befestigung eines Hörhilfegerätes oder einer Otoplastik im Ohr
|
|
US7143607B2
(en)
*
|
2003-08-27 |
2006-12-05 |
Heart & Company |
Jewelry article having interchangeable setting and capture module
|
|
CA2542121A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Genomically modified cell neutralized to serum-free system
|
|
EP2332990A1
(en)
*
|
2004-03-19 |
2011-06-15 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
|
EP1700533A1
(fr)
*
|
2005-03-11 |
2006-09-13 |
Bruno Fillacier |
Dispositif pour maintenir un objet d'orfèvrerie aux lobes des oreilles
|
|
EP1754991A1
(en)
*
|
2005-08-18 |
2007-02-21 |
Yu-Teng Hsiao |
Movable magnetic coupling system for securing a one-piece lens to a cap visor
|
|
US20070083237A1
(en)
*
|
2005-10-12 |
2007-04-12 |
Teruel Elberto B |
Magnetic therapeutic device and method of using the same
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US8991210B1
(en)
|
2011-08-19 |
2015-03-31 |
Cary Stewart, Jr. |
Revolving jewelry system
|
|
MY169358A
(en)
|
2011-08-23 |
2019-03-26 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2013026835A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab fragments and methods of use
|
|
MX349095B
(es)
|
2011-08-23 |
2017-07-11 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno.
|
|
CA2876285A1
(en)
|
2012-08-08 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
|
EP2882775B1
(en)
|
2012-08-09 |
2018-02-14 |
Roche Glycart AG |
Asgpr antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
MX375359B
(es)
|
2013-02-26 |
2025-03-06 |
Roche Glycart Ag |
Moléculas biespecíficas de unión a antígeno activadoras de células t.
|
|
CA2896359A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
US20150325352A1
(en)
*
|
2014-05-07 |
2015-11-12 |
Anker Technology Co., Limited |
Magnet fixed device and an electronic device having the same or an accessory having the same
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
CR20170194A
(es)
|
2014-11-14 |
2017-07-10 |
Hoffmann La Roche |
Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055388A2
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
CR20180453A
(es)
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
EP3455254B1
(en)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
AU2017384126B2
(en)
|
2016-12-20 |
2025-01-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
KR20200084006A
(ko)
|
2017-11-01 |
2020-07-09 |
에프. 호프만-라 로슈 아게 |
표적화된 ox40 작용제를 사용하는 병용 요법
|
|
BR112020006443A2
(pt)
|
2017-11-01 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
SG11202005632SA
(en)
|
2017-12-21 |
2020-07-29 |
Hoffmann La Roche |
Antibodies binding to hla-a2/wt1
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
IL277174B2
(en)
|
2018-03-13 |
2025-12-01 |
Hoffmann La Roche |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CR20200459A
(es)
|
2018-04-13 |
2020-11-11 |
Hoffmann La Roche |
Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
|
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
|
|
TWI861039B
(zh)
|
2018-12-21 |
2024-11-11 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之促效cd28抗原結合分子
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
JP2022538075A
(ja)
|
2019-06-26 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体結合ｃｅａ及び４－１ｂｂｌの融合
|
|
JP7354306B2
(ja)
|
2019-06-27 |
2023-10-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
MX2022008214A
(es)
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
|
PH12022552436A1
(en)
|
2020-04-15 |
2024-01-03 |
Hoffmann La Roche |
Immunoconjugates
|
|
CA3177239A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific antibodies
|
|
CN115916827A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
免疫活化Fc结构域结合分子
|
|
CN115702168A
(zh)
|
2020-06-23 |
2023-02-14 |
豪夫迈·罗氏有限公司 |
靶向Her2的激动性CD28抗原结合分子
|
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
|
AU2021393752A1
(en)
|
2020-12-04 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US20240262913A1
(en)
|
2021-03-09 |
2024-08-08 |
Hoffmann-La Roche Inc. |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
JP2024508949A
(ja)
|
2021-03-09 |
2024-02-28 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－１標的化ｉｌ－２変異体イムノコンジュゲートとｆａｐ／４－１ｂｂ結合分子との併用療法
|
|
EP4314032A1
(en)
|
2021-03-30 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Protease-activated polypeptides
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
JP2024543257A
(ja)
|
2021-11-26 |
2024-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
JP2025534285A
(ja)
|
2022-09-29 |
2025-10-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ポリペプチド
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4651885A1
(en)
|
2023-01-20 |
2025-11-26 |
F. Hoffmann-La Roche AG |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
EP4720121A1
(en)
|
2023-06-01 |
2026-04-08 |
F. Hoffmann-La Roche AG |
Immunostimulatory antigen binding molecules that specifically bind to bcma
|
|
EP4720120A1
(en)
|
2023-06-01 |
2026-04-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies targeting bcma and cd28
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|